US equities |
AMD $506.57 ▲+4.68% NVDA $205.26 ▼-0.69% SPCX $136.51 ▼-3.40% AMZN $269.20 ▲+7.38% AAPL $349.77 ▲+5.38% TSLA $383.24 ▼-3.83% MU $846.70 ▼-0.98% META $631.18 ▲+1.64%
FinancialContent

Ardelyx, Inc. - Common Stock (NQ:ARDX)

3.290 +0.260 (+8.58%)
Delayed Quote Updated: 9:45 AM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Top movers in Thursday's after hours session ↗
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Ardelyx Inc (NASDAQ:ARDX) Stock Surges on Q3 2025 Revenue Beat and Raised Guidance ↗
Ardelyx (ARDX) stock surged 15% after Q3 2025 results, beating revenue estimates with strong growth from its drug IBSRELA and raising its full-year guidance. 
Via Chartmill
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
News headline image
4 Analysts Assess Ardelyx: What You Need To Know ↗
 
Via Benzinga
Ardelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions Coming ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 4, 2025 ↗
 
Via Benzinga
News headline image
What to Expect from Ardelyx's Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Participate in Upcoming Investor Conferences
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Q2 Revenue Jumps 33% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are moving after the closing bell on Monday? ↗
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Ardelyx Inc (NASDAQ:ARDX) Surges 11.6% After Q2 2025 Earnings and Revenue Beat Estimates ↗
Ardelyx (ARDX) Q2 2025 earnings beat estimates with $97.7M revenue (+33% YoY) and -$0.08 EPS. Strong IBSRELA & XPHOZAH sales drove growth, sparking an 11.6% after-hours stock surge. 
Via Chartmill
Topics Earnings
News headline image
Ardelyx Announces Changes to the Executive Leadership Team
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >